GHRP-2 (Pralmorelin): Clinical Overview and 503A Status

GHRP-2, also known as pralmorelin or KP-102, is a synthetic growth hormone releasing peptide. Among clinicians working in this space it is best known for two things: it is an effective secretagogue, and it is restricted from routine 503A compounding. Both facts matter, and the second is the one most often stated inaccurately.

This guide situates GHRP-2 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is GHRP-2?

GHRP-2 is a synthetic hexapeptide — six amino acids — developed as a growth hormone secretagogue. It acts at the same receptor ghrelin does, the growth hormone secretagogue receptor GHS-R1a, and is administered by subcutaneous injection.

It belongs to the growth hormone releasing peptide family, the older generation of secretagogues that preceded the more selective agents. Understanding where it sits in that lineage explains both why it works and why it has largely been displaced. The broader class is covered in our growth hormone peptides guide.

The selectivity problem

GHRP-2 reliably stimulates growth hormone release. The complication is what else it stimulates. GHRP-2 also produces measurable increases in prolactin and cortisol, and to a lesser extent ACTH.

This is the defining clinical distinction between the older GHRPs and a selective agent such as ipamorelin, which was specifically engineered to stimulate growth hormone with minimal effect on those other axes. Elevated cortisol works directly against most of the metabolic goals patients pursue when they ask about growth hormone, and sustained prolactin elevation has its own endocrine consequences.

That selectivity gap, not efficacy, is the reason the field moved on. A secretagogue that raises the stress hormone alongside the growth hormone is a blunter instrument than the alternatives.

What the 503A restriction actually means

GHRP-2 is restricted from routine 503A compounding. Precision matters here, because this area is widely misdescribed.

Most peptides used in this field are not FDA-approved drugs; they reach patients through pharmacy compounding, which is governed by the 503A bulk drug substances list. Substances the FDA has placed in Category 2 carry a determination of significant safety risk and are effectively unavailable for routine compounding. GHRP-2 sits within that restricted space.

Two clarifications follow. First, a restriction is not merely a paperwork obstacle — it reflects a regulatory determination, and compounding outside those rules is not a gray area. Second, this landscape has moved repeatedly since 2023, including a set of removals from Category 2 in April 2026 that did not include GHRP-2. Status should be verified at the time of the conversation rather than recalled from an older protocol. Our peptide formulary tracks current status for every agent.

How this comes up in practice

For most clinicians GHRP-2 is not a prescribing decision but a question to answer. Patients arrive having read older protocols, or having purchased material online where it is sold freely as a research chemical with no verified identity, purity or dose.

The accurate answer has three parts: the pharmacology is real, the selectivity is inferior to newer agents, and the regulatory position rules out legitimate compounded supply. Patients interested in the growth hormone axis are better served by a conversation about what the axis can and cannot deliver — covered in our growth hormone peptides overview — than by substituting one unregulated compound for another.